SCHEMBL6085751

SCHEMBL6085751

O=S(=O)(Nc1ccc(-c2n[nH]cc2-c2nc3ccccc3o2)cc1)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 17/20 0.71
PTPN5 P54829 17/20 0.71
PTPN2 P17706 16/20 0.71
MAPT P10636 4/20 0.71
MEN1 O00255 2/20 0.71
HPGD P15428 2/20 0.71
KMT2A Q03164 2/20 0.71
HSD17B10 Q99714 1/20 0.71
HSPD1 P10809 11/20 0.60
HSPE1 P61604 11/20 0.60
KDM4E B2RXH2 1/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
LMNA P02545 1/20 0.53
TP53 P04637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6201863 0.92 PTPN1 (0.74) PTPN1PTPN5PTPN2MAPTMEN1
SCHEMBL6087192 0.87 PTPN5 (0.52) PTPN1PTPN5PTPN2MAPTMEN1
SCHEMBL6086234 0.86 PTPN5 (0.74) PTPN1PTPN5PTPN2MAPTMEN1
SCHEMBL6084255 0.86 PTPN2 (0.58) PTPN1PTPN5PTPN2MAPTMEN1
SCHEMBL6085931 0.85 PTPN5 (0.52) PTPN1PTPN5PTPN2MAPTMEN1
SCHEMBL6086240 0.85 PTPN5 (0.61) PTPN1PTPN5PTPN2MAPTMEN1
SCHEMBL6086906 0.82 PTPN1 (0.60) PTPN1PTPN5PTPN2MAPTMEN1
SCHEMBL6085204 0.81 PTPN1 (0.61) PTPN1PTPN5PTPN2MAPTMEN1
SCHEMBL6086529 0.81 NPC1 (0.54) MAPTMEN1HPGDKMT2AHSD17B10
SCHEMBL6083635 0.80 PTPN1 (0.56) PTPN1PTPN5PTPN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 PTPN1 344/4885PTPN5 362/4885PTPN2 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.